Medication Supply Disruption

posted May 29, 2018, 8:58 PM by Chong Ching Wern   [ updated Jul 3, 2018, 7:55 PM ]
28 May 2018 (Circular No. SP PPUM: 196/2018): 

The following medications will be facing supply disruptions:

No.

Name of Medication

Formulary Category

Cause / Action by Pharmacy

Estimated Stock Recovery

Alternative Medication


1)

Albumin Human 20% Injection



Standard Formulary

· Production issues by Grifols Malaysia Sdn. Bhd.

· Usage is only reserved for critical cases including 'replacement after large volume parecentesis'.


Until further notice.

None, other companies are also experiencing stock issues.

Please contact Inpatient Pharmacy first for elective surgeries. 

2)

Co-Trimoxazole 480mg Injection



Standard Formulary

· Production issues by Pfizer (M) Sdn. Bhd.

· Supply limited to patients who are unable to tolerate oral therapy. 


August 2018.

Consider use of Co-Trimoxazole 480mg Tablet in view of its oral bio-availability is comparable to the injection.

3)

Ketamine 500mg/10mL Injection

Standard Formulary

· Production issues by Duopharma (M) Sdn. Bhd. and Pharmaniaga Sdn. Bhd.



Until further notice.

Consider use of other anaesthesias which are available in our Standard Formulary.

4)

Prothrombin Complex (Factor II, VII, IX, X) Injection (Octoplex)


Standard Formulary

· Stock supply issues by Pharmaniaga Marketing Sdn. Bhd.

Early July 2018.

None.

5)

Ropivacaine 150mg/20mL Injection (Naropin)

Standard Formulary

· Stock supply issues by Aspen Malaysia Sdn. Bhd.

· Supply of medication will be controlled by Inpatient Pharmacy. 


Until further notice.

None, will notify when all stocks have been used up.

6)

Dosulepin 75mg Tablet

Standard Formulary

· Production issues by all distributors for this medication in Malaysia.


Until further notice.

Dosulepin 25mg Tablet will be used.

7)

Cisplatin 50mg/50mL Injection

Standard Formulary

· Production issues by Pfizer (M) Sdn. Bhd. and other manufacturers.

· Sorting out supplies from companies that still have leftover stocks.


Until further notice.

None, doctors are encouraged not to start new patients on this medication.